Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review

Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review

Glioblastoma multiforme (GBM) is one of the most frequent and aggressive primary tumors in the central nervous system, representing more than 60% of all brain tumors in adults. Primary GBM remains incurable with a poor prognosis both for limited therapeutic alternatives and for a high risk of progre...

Full description

Bibliographic Details
Main Authors: Mario Pirozzi, Marianna Caterino, Sergio Facchini, Alessia Zotta, Gaetana Messina, Raffaele Rauso, Antonello Sica, Donato Sciano, Gaetano Facchini, Michele Orditura, Teresa Somma, Francesco Maiuri, Paolo Cappabianca, Fortunato Ciardiello, Morena Fasano
Format: Article
Language:English
Published: Karger Publishers 2022-06-01
Series:Case Reports in Oncology
Subjects:
glioblastoma
regorafenib
advanced treatment lines
long survival
Online Access:https://www.karger.com/Article/FullText/524954

Internet

https://www.karger.com/Article/FullText/524954

Similar Items